Tempus AI, Inc. (NASDAQ:TEM) Given Average Recommendation of “Hold” by Brokerages

Tempus AI, Inc. (NASDAQ:TEM) has been given a consensus rating of “Hold” by the thirteen brokerages that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and six have issued a buy rating on the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $87.20.

TEM has been the topic of several recent research reports. Morgan Stanley raised their price objective on shares of Tempus AI from $80.00 to $85.00 and gave the company an “overweight” rating in a research report on Monday, December 1st. Needham & Company LLC lifted their price objective on shares of Tempus AI from $70.00 to $100.00 and gave the company a “buy” rating in a research note on Wednesday, November 5th. TD Cowen cut shares of Tempus AI from a “buy” rating to a “hold” rating in a report on Tuesday, October 21st. Canaccord Genuity Group cut their target price on Tempus AI from $95.00 to $80.00 and set a “buy” rating on the stock in a report on Monday, December 22nd. Finally, JPMorgan Chase & Co. decreased their price target on Tempus AI from $85.00 to $80.00 and set a “neutral” rating for the company in a research note on Monday, December 15th.

Tempus AI Price Performance

TEM opened at $55.97 on Wednesday. The stock has a fifty day moving average price of $67.79 and a 200 day moving average price of $74.07. The company has a current ratio of 3.28, a quick ratio of 3.12 and a debt-to-equity ratio of 2.45. Tempus AI has a 1 year low of $36.22 and a 1 year high of $104.32. The stock has a market cap of $9.96 billion, a price-to-earnings ratio of -47.03 and a beta of 5.22.

Tempus AI (NASDAQ:TEM) last posted its quarterly earnings results on Tuesday, November 4th. The company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.05. The company had revenue of $334.21 million during the quarter, compared to the consensus estimate of $328.89 million. Tempus AI had a negative return on equity of 73.21% and a negative net margin of 18.45%.The business’s quarterly revenue was up 84.7% on a year-over-year basis. During the same period last year, the business earned ($0.46) EPS. Analysts forecast that Tempus AI will post -6.15 EPS for the current fiscal year.

Insider Activity

In other Tempus AI news, Director Jennifer A. Doudna sold 676 shares of the stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $75.55, for a total transaction of $51,071.80. Following the transaction, the director owned 23,952 shares in the company, valued at $1,809,573.60. This trade represents a 2.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO James William Rogers sold 19,966 shares of the company’s stock in a transaction on Thursday, December 11th. The stock was sold at an average price of $73.20, for a total transaction of $1,461,511.20. Following the sale, the chief financial officer directly owned 111,250 shares of the company’s stock, valued at approximately $8,143,500. This represents a 15.22% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 761,212 shares of company stock valued at $51,975,849. Insiders own 26.27% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in TEM. Cranbrook Wealth Management LLC bought a new position in Tempus AI during the third quarter valued at about $25,000. Concord Wealth Partners raised its stake in shares of Tempus AI by 308.0% in the second quarter. Concord Wealth Partners now owns 408 shares of the company’s stock valued at $26,000 after purchasing an additional 308 shares in the last quarter. JPL Wealth Management LLC bought a new position in Tempus AI in the third quarter worth $26,000. GAMMA Investing LLC acquired a new stake in Tempus AI during the third quarter worth $28,000. Finally, Allworth Financial LP boosted its stake in Tempus AI by 5,000.0% during the second quarter. Allworth Financial LP now owns 459 shares of the company’s stock worth $29,000 after buying an additional 450 shares in the last quarter. Institutional investors own 24.22% of the company’s stock.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.